188 results about "Diabetic nephropathy" patented technology

The invention relates to the technical field of medical health big data analysis, in particular to a diabetic nephropathy risk identification method and system based on big data analysis, and the method comprises the following steps: screening key index features of risk patients through big data analysis based on health risk data of diabetic nephropathy patients; association of key indexes of the risk patients is analyzed, risk index interaction features are extracted, risk feature constraint conditions are determined, virtual sample parameters are identified through multi-dimensional data association, and a virtual sample set of the risk patients is established. According to the method, interaction characteristic values are extracted by analyzing key indexes of risk patients, high-risk index association is accurately captured, coverage and balance are enhanced based on multi-dimensional data association, non-stationary influence is solved by combining time sequence key change rate and shear point identification, and accurate matching is realized by analyzing offset rate and change trend. And the overall risk level is quantitatively evaluated by integrating interval data weighting, so that the risk identification comprehensiveness and the result reliability are improved.

The invention relates to the field of medical information processing and traditional Chinese medicine curative effect evaluation, in particular to a diabetic nephropathy traditional Chinese medicine curative effect evaluation method based on patient report outcome. The method comprises the following steps: searching related symptoms and clinical characterization data of diabetic nephropathy through a medical database, extracting target entries, performing language standardization processing, constructing an initial candidate entry set, calculating the occurrence frequency of each symptom entry, and screening entries meeting a set threshold value to form an entry set; carrying out dimension division on the entry set according to feature attributes to form a preliminary dimension structure set; forming a screening result set through preset logic screening conditions; and carrying out weighted regression fusion on the comprehensive curative effect score and clinical detection data, and outputting a patient curative effect index. In an item weight determination process, dynamic balance between subjective experience and objective statistical information is realized through a mixed weighting model, and the defects of strong subjectivity of expert scoring and large result fluctuation in a traditional method are overcome.

A class of compounds and the use thereof in a drug. Specifically, the present invention relates to a class of new compounds, a pharmaceutical composition containing the compounds, a method for preparing the compounds, and the use of the compounds or the pharmaceutical composition in the preparation of a drug for treating GLP-1 receptor agonist-mediated diseases and / or disorders, particularly the use in the preparation of a drug for treating diabetes, non-alcoholic fatty liver disease, obesity, myocardial infarction, heart failure, diabetic nephropathy, Parkinson's disease and Alzheimer's disease.

The invention discloses a diabetic nephropathy risk assessment and prediction system based on platelet indexes, and particularly relates to the technical field of disease risk prediction, which comprises a platelet index acquisition module, a drug use data acquisition module, a drug intervention assessment module, an index correction module, a clustering analysis module and a diabetic nephropathy risk assessment module, the method comprises the following steps: acquiring platelet related detection indexes and historical medication data of a patient, calculating a drug intervention influence index and generating a correction factor, realizing platelet index reverse reduction correction by adopting a convolutional neural network model, determining a similar group in combination with clustering analysis, and dynamically evaluating the risk of diabetic nephropathy based on the average morbidity of the group. Personalized accurate prediction is realized; the platelet index correction accuracy is improved, individualized drug intervention elimination is achieved, the similar population clustering analysis precision is enhanced, diabetic nephropathy risk prediction is dynamically adjusted in combination with comprehensive scores, and the early screening and individualized intervention effects are improved.

The invention provides a diabetic nephropathy early warning method, system, equipment and medium, and relates to the technical field of medical data analysis and prediction.The method comprises the steps that multiple urine samples of a user are collected, target urine protein detection is conducted, and multiple urine protein concentrations are obtained; each urine protein concentration is combined with a normal urine protein concentration set to be input into an abnormal data recognition tree, the number of layers of multiple recognition nodes is obtained, and the detection confidence coefficient is obtained through calculation; configuring an abnormal proportion according to the detection confidence coefficient, inputting a plurality of urine protein concentration combination normal urine protein concentration sets into an abnormal data identification tree, deleting urine protein concentrations divided into abnormal data in the abnormal proportion before, and obtaining screened urine protein concentrations; according to the screened urine protein concentration, an auxiliary early warning coefficient is obtained through calculation, and early warning is carried out. The technical problem of low early warning accuracy of diabetic nephropathy in the prior art is solved.

The invention relates to application of targeted intervention FBP2mRNA in preparation of a medicine for preventing and treating diabetic nephropathy, and belongs to the technical field of biomedicine. The invention provides an application of FBP2mRNA as a therapeutic target in preparation of a medicine for preventing and treating diabetic nephropathy. The NCBI (National Center of Biotechnology Information) login number of the FBP2mRNA is NM003837.4. The invention also provides an application of the shRNA for specifically interfering with the expression of the FBP2mRNA in the preparation of a medicine for preventing and treating diabetic nephropathy, wherein the nucleotide sequence of the shRNA is shown as SEQ ID NO. 1. It is found for the first time that targeted inhibition of the expression level of FBP2mRNA can effectively reduce the lipid level in mouse glomerular podocytes, reduce the expression level of lipid synthesis related genes and reduce the activity of lipid synthesis protein, and then the effect of treating diabetic nephropathy is achieved, so that FBP2mRNA can be used as a drug treatment target, and the treatment effect of diabetic nephropathy is improved. The application is applied to research, development and preparation of diabetic nephropathy prevention and treatment medicines.

The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for promoting healthy aging of skin, the treatment of skin disorders, the treatment of cardiovascular disorders, the treatment of renal disorders, the treatment of angiogenesis disorders, such as cancer, treatment of tissue damage, such as non-cardiac tissue damage, the treatment of evolving myocardial infarction, the treatment of ischemic injury, and the treatment of various other disorders, such as complications arising from diabetes with the compounds and compositions of the invention. Other disorders can include, but are not limited to, atherosclerosis, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, diabetic cardiomyopathy, infections of the skin, peripheral vascular disease, stroke, asthma, and the like.

The invention provides a traditional Chinese medicine composition for treating diabetic nephropathy and application thereof, and belongs to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition provided by the invention is prepared from the following raw materials in parts by weight: 30 to 120 parts of raw radix astragali seu hedysari, 10 to 20 parts of radix pseudostellariae, 5 to 15 parts of herba dendrobii, 5 to 15 parts of radix trichosanthis, 10 to 20 parts of radix rehmanniae recen, 10 to 20 parts of raw radix puerariae, 25 to 35 parts of herba agrimoniae, 5 to 15 parts of rhizoma discoreae, 10 to 20 parts of fructus corni, 10 to 20 parts of ramuli euonymi, 10 to 20 parts of serissa serissoide, 25 to 35 parts of chinaroot greenbrier, 4 to 8 parts of fructus schisandrae chinensis, 10 to 20 parts of herba pyrolae and 10 to 20 parts of corn stigma. The traditional Chinese medicine composition disclosed by the invention can be used for improving the clinical curative effect, improving symptoms, repairing podocyte damage and relieving oxidative stress by virtue of unique traditional Chinese medicine composition and aiming at pathogenesis treatment of the DN with the syndrome of deficiency of both qi and yin, and a new thought and a new method are provided for traditional Chinese medicine treatment of the DN.

The invention belongs to the technical field of medicines, and particularly relates to application of BMP9 as an intervention target in preparation of a medicine for treating diabetic nephropathy. More specifically, the invention provides application of a BMP9 accelerant in preparation of a medicine for preventing and / or treating diabetic nephropathy. The BMP9 accelerant is a substance shown in the following (i) or (ii): (i) a substance for increasing the content of BMP9 in a subject; (ii) a substance that increases BMP9 activity in a subject. According to the invention, a DKD mouse model is constructed, and liver RNA-seq sequencing is carried out, such that a differential expression gene BMP9 exists between a normal mouse and a DKD mouse. It is found that BMP9 can be used as a new target for prevention and treatment of DKD and has important theoretical significance and potential clinical application value.

The invention relates to the technical field of image processing, in particular to a tongue picture auxiliary identification method and system for a diabetic nephropathy patient and a medium. The method comprises the steps of obtaining tongue picture region images, clustering the tongue picture region images based on preset different numbers of clustering clusters, and screening an optimal clustering result according to a clustering result; obtaining the attribution degree of each pixel point in each cluster in the optimal clustering result by combining the gray scale gradient rule of the pixel points in different directions in the neighborhood of each pixel point and the relative position relationship between the pixel points and each cluster in the optimal clustering result; according to the difference of the attribution degrees of each pixel point and the neighborhood pixel points thereof in the same cluster in the optimal clustering result, acquiring the attribution expression degree of each pixel point and each cluster in the optimal clustering result; and according to the affiliation representation degree and the initial membership degree of each pixel point and each cluster in the optimal clustering result, the tongue picture region image is divided again. According to the invention, the accuracy of the tongue picture region image division result is improved.

The invention discloses a rapid detection device for diabetic nephropathy patients, and belongs to the technical field of diabetic nephropathy patient detection.The rapid detection device comprises a blood glucose detection assembly, a self-adaptive adjusting mechanism, an extrusion force adjusting structure and an automatic blood taking mechanism, and the self-adaptive adjusting mechanism is arranged on the blood glucose detection assembly; the extrusion force adjusting structure is arranged in the blood glucose detection assembly, the extrusion force adjusting structure is connected with the self-adaptive adjusting mechanism, the extrusion force adjusting structure comprises an adjusting assembly and a reciprocating displacement assembly, and the automatic blood taking mechanism is arranged on the blood glucose detection assembly. By arranging the self-adaptive adjusting mechanism, the extrusion force adjusting structure and the automatic blood taking structure, the extrusion force for assisting the blood taking structure of the person to be detected is self-adaptively adjusted according to different thicknesses of the hands of the person to be detected, and it is ensured that the device can take out sufficient blood for detection; and tissue fluid groups which influence a detection result can be prevented from existing in blood, so that the detection precision of the device is improved.

The invention relates to the technical field of medical artificial intelligence diagnosis, and discloses a diabetic nephropathy auxiliary identification method based on multi-source data. The method comprises the following steps: starting a medical data traceability process, capturing original indexes from a multi-heterogeneous system, and arranging the original indexes into an initial data set; and performing hierarchical data fusion according to the pathological evolution knowledge graph to generate a fusion health record with a timestamp. And introducing a dynamic feature weaving process, and extracting a multi-level abnormal feature network from the physiological parameter trajectory according to the priority of the biomarker. And importing the abnormal feature network into a progressive mode learning process, training an identification engine for mapping feature combinations to different disease risk levels, and outputting an identification conclusion by the engine. According to the method, the structured abnormal mode network is constructed through priority-driven dynamic feature weaving, and the recognition engine is trained by using a progressive learning mechanism, so that the accuracy and clinical interpretability of risk stratification of diabetic nephropathy are improved.

The invention relates to the technical field of biological medicine, and discloses an application of an Aspisin small-molecule inhibitor in preparation of a medicine for preventing and / or treating diabetic nephropathy, and the Aspisin small-molecule inhibitor comprises ganoderic acid DM. The inhibitor ganoderic acid DM targeting Aspisin is screened from a bioactive compound library by combining high-throughput virtual drug screening with biological activity screening, it is found that ganoderic acid DM can be specifically combined with Aspisin and shows high affinity, and it is expected that an experimental basis is provided for clinical treatment and prevention of DKD and new drug research and development.

The invention relates to a non-invasive diabetic nephropathy grading and predicting method supporting convenient screening, which comprises the following steps: acquiring and preprocessing a color fundus image and non-invasive clinical features of a diabetic patient to obtain a multi-modal data set, and setting marks of various severity degrees of diabetic nephropathy; constructing a deep learning model A1, and obtaining diabetic nephropathy severity prediction probability distribution # imgabs0 # based on the color fundus image according to the multi-modal data set; a deep learning model A2 is constructed, and diabetic nephropathy severity prediction probability distribution # imgabs1 # based on clinical data is obtained according to the multi-modal data set; and constructing a fusion model, fusing the obtained diabetic nephropathy prediction probabilities by the fusion model through a self-adaptive weight distribution algorithm, dynamically adjusting the weight according to the prediction result output by each model, calculating a comprehensive diabetic nephropathy severity score, and outputting a final diabetic nephropathy prediction grading result according to the score.

The invention provides a kidney prognosis risk prediction method and system for a patient diagnosed as type 2 diabetic nephropathy through pathology, and relates to the technical field of prognosis risk prediction.The method comprises the steps that clinical data of the T2DN patient meeting the screening standard are obtained; screening the clinical data through an LASSO regression method so as to screen out key clinical indexes related to kidney prognosis; based on the key clinical indexes, constructing a risk prediction model by using a Cox proportional risk model; performing performance analysis on the risk prediction model by using clinical data of the training queue and the verification queue, and performing internal verification on the risk prediction model by using a Bootstrap method to ensure the robustness and reliability of the model; and inputting clinical data of a to-be-tested patient into the risk prediction model to obtain a prediction result. By screening key clinical indexes, an individualized risk prediction model is constructed, and a scientific basis is provided for clinical early intervention.

The present invention discloses phenyl-substituted dihydronaphthyridine compounds a preparation therefor and a use thereof, and belongs to the technical field of medicine. The compounds disclosed in the present invention are represented by formula I, and can be used as a mineralocorticoid receptor antagonist for treating, preventing or alleviating aldosteronism hyperplasia, diabetic nephropathy, hypertension, heart failure (comprising chronic heart failure, etc.), sequelae of myocardial infarction, liver cirrhosis, renal failure, stroke and other diseases in patients.

The invention relates to the technical field of molecular biology, in particular to a methylation marker for diagnosis of diabetic nephropathy. Specifically, the methylation marker comprises a P site of a CAT gene promoter region and / or an E site of a CAT gene exon 1 region. Based on a detection system combining methylation sensitive restriction enzyme with quantitative PCR, the kit has the advantages of simplicity and convenience in operation, good repeatability, accuracy in quantification and easiness in standardization, and is suitable for low-invasive samples such as peripheral blood. By effectively distinguishing pure type 2 diabetes patients from diabetic nephropathy combined patients, a reliable technical means is provided for risk stratification, early intervention and dynamic monitoring of diabetic people, and the method has good clinical application prospects and popularization value.

The present invention relates to a pyridine polycyclic compound inhibitor, a preparation method therefor and a use thereof. In particular, the present invention relates to a compound represented by formula (I), a preparation method therefor, a pharmaceutical composition comprising the compound, and a use of the compound in a medication for treating chronic kidney disease, kidney or cardiac fibrosis, diabetic nephropathy, congestive heart failure, hypertension, primary aldosteronism, and Cushing syndrome, wherein the definitions of the substituents in formula (I) are the same as those in the description.

To provide methods of treating metabolic diseases and disorders using an antigen binding protein specific for the GIPR polypeptide.SOLUTION: In various embodiments, a metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments, the antigen binding protein is administered in combination with a GLP-1 receptor agonist.SELECTED DRAWING: None

The invention discloses a biomarker, application of the biomarker in predicting the risk of diabetic nephropathy and a kit, which can realize non-invasive efficient evaluation on the severity of diabetic nephropathy and provide important supplement for early diagnosis and refined risk stratification of diabetic nephropathy. The ratio of the Sulfatase-1 to the creatinine Cr is uSULF1 / Cr, and the Sulfatase-1 and the creatinine Cr are both from urine.

The present disclosure relates to peptide fragments derived from interleukin-4 (IL-4) for the treatment of diabetic nephropathy.

The invention discloses core components, targets and action mechanisms of Zhibai Dihuang pills / decoction for treating early diabetic nephropathy based on a directed PPI network and a plurality of network centrality algorithms. Core components and targets of the Zhibai rehmannia pill / decoction for treating diabetic nephropathy are determined through the steps of screening active components of the Zhibai rehmannia pill / decoction, collecting target information corresponding to the active components, collecting disease related targets, obtaining drug-disease intersection genes, constructing a directed protein interaction network and the like. The action mechanism of the Zhibai rehmannia pill / decoction for treating diabetic nephropathy is researched. The invention provides a scientific theoretical basis for the treatment of diabetic nephropathy by the Zhibai Dihuang pill / decoction, and provides a new method for the clinical treatment and scientific research of the Zhibai Dihuang pill / decoction on diabetic nephropathy.

This invention relates to double-stranded oligonucleotides complementary to JAK1 that result in the regulation of JAK1 expression. Regulation of JAK1 expression is beneficial for a range of medical disorders, including inflammatory bowel disease, organ transplant rejection, graft-versus-host disease, multiple sclerosis, rheumatoid arthritis (RA), juvenile idiopathic arthritis, psoriasis, dermatitis, diabetic nephropathy, systemic lupus erythematosus (SLE), dry eye disease, cancer, myelofibrosis, and asthma. The invention also includes compositions comprising double-stranded oligonucleotides and therapeutic methods using double-stranded oligonucleotides.

The application discloses a kind of based on multi-source medical text construction traditional Chinese medicine diabetic nephropathy knowledge graph method and system, including following module: data integration module: integration diagnosis and treatment guideline and electronic medical record, after redundancy, terminology standardization constructs unified medical data set;Mixed labeling and entity recognition module: fusion artificial labeling and BERT-BiLSTM-CRF model automatically identifies traditional Chinese medical syndrome, traditional Chinese medicine and other complex entities;Relationship modeling module is based on semantic embedding and multi-label classification algorithm, accurately constructs traditional Chinese and western medicine association rules;Atlas application module: entity relationship is converted into attribute graph structure, supports graph database interactive query, realizes diagnosis and treatment recommendation, contraindication early warning and curative effect analysis.Through the above scheme, the present application significantly improves the accuracy of differentiation, reduces the risk of drug contraindication, provides efficient, interpretable decision support for the prevention and treatment of diabetic nephropathy, has important clinical value and popularization potential.

Disclosed herein is a deuterated compound of Formulas (I) and (II) as an FTO inhibitor with improved pharmacokinetic properties with comparable selective FTO inhibition. Also disclosed herein is a pharmaceutical composition comprising the same, and a method of inhibiting weight gain, promoting weight loss, reducing serum LDL, cholesterol, LDL-c, or triglycerides, or treating obesity or an obesity-related disease (esp. obesity-related diabetes, hyperglycemia, diabetic nephropathy, hyperlipemia, coronary heart disease, atherosclerosis, hypertension, cardiovascular or cerebrovascular disease) or Alzheimer's disease by inhibiting FTO by using the compound disclosed herein.

Methods of treating diseases and disorders treatable by AMPK activation with sephin1 and related compounds, for example metabolic syndrome, non-alcoholic fatty liver disease, nonalcoholic steatohepatitis (NASH), obesity, type 2 diabetes, insulin resistance, glucose intolerance, chronic pain, sarcopenia, a neuromuscular disorder, heart failure, cardiac hypertrophy, diabetic cardiomyopathy, cardiac reperfusion injury, chronic kidney disease, polycystic kidney disease, diabetic nephropathy, cardiovascular diseases, inflammatory bowel disease, arthritis, hypertension, peripheral vascular disease, nephrogenic diabetes insipidus, glaucoma, an eye disease or disorder, ocular neovascularization, β-hemoglobinopathy, cancer, fibrosis, cancer cachexia, and mitochondrial disease.

The present invention provides a compound represented by general formula (I) or a pharmaceutically acceptable salt, precursor, or solvate thereof, and a use thereof in the preparation of a drug for diagnosing diabetic nephropathy. General formula (I), wherein X is selected from carbon or nitrogen; R1 is selected from hydrogen or alkyl; R2 is one or more substituents on the benzene ring or the pyridine ring, and R2 is independently selected from one or more of hydrogen, halogen, hydroxyl, cyano, nitro, amino, C1-C6 alkyl, C3-C6 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C3-C6 cycloalkoxy, C1-C6 alkylamino, C3-C6 cycloalkylamino, halo C1-C6 alkyl, halo C3-C6 cycloalkyl, halo C1-C6 alkoxy, halo C3-C6 cycloalkoxy, halo C1-C6 alkylamino, halo C3-C6 cycloalkylamino, C6-C8 aryl, or C5-C8 heteroaryl, and in these substituents represented by R2, at least one atom or the entire substituent is replaced by a radionuclide. The drug and method for diagnosing diabetic nephropathy according to the present invention relate to non-invasive diagnosis technology and have the advantages of causing less pain to a subject and having less contraindications.

The invention discloses a tricyclic compound as well as a preparation method and application thereof. In particular, the present invention relates to a compound represented by general formula (I), a preparation method thereof, a pharmaceutical composition containing the compound, and uses of the compound in drugs for treating chronic kidney disease, renal or cardiac fibrosis, diabetic nephropathy, congestive heart failure, hypertension, primary aldosteronism and Cushing's syndrome, wherein each substituent in the general formula (I) is as defined in the specification.

The invention discloses application of an SNP (Single Nucleotide Polymorphism) site in predicting the occurrence risk of type 2 diabetic nephropathy, and belongs to the technical field of biological detection. The application finds that the SNP site rs5741812 of the lipopolysaccharide binding protein (LBP) has obvious correlation with the occurrence of the type 2 diabetic nephropathy for the first time, and prompts that the rs5741812 can be used as a marker for predicting or assisting in predicting the occurrence risk of the type 2 diabetic nephropathy, so that the sensitivity and the specificity of predicting the occurrence risk of the type 2 diabetic nephropathy are improved; the method has important significance on clinically predicting early-stage type 2 diabetic nephropathy.

The present disclosure relates to SH3YL1 monoclonal antibodies and compositions comprising the SH3YL1 monoclonal antibodies. The disclosure also relates to isolated nucleic acid molecules encoding the SH3YL1 antibodies, vectors comprising the nucleic acid molecules, and host cells comprising the vectors. Also disclosed are methods of modulating an immune response, methods of treating diabetic nephropathy, and methods of treating non-alcoholic steatosis hepatitis comprising administering the SH3YL1 antibodies. Also disclosed are methods of treating acute kidney injury and methods of treating inflammatory bowel disease comprising administering the SH3YL1 antibodies.